Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Welcome and Introduction to Vi3C

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Sep

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Welcome and Introduction to Vi3C

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Misconceptions Regarding Skin Cancer Risk in the United States

Advanced Refractory Melanoma Addition of Tilsotolimod to Ipilimumab

Novel Strategy May Enhance Sensitivity of Monitoring Cancer in Blood Samples

Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases

Can ctDNA Monitoring Help to Predict Melanoma Recurrence